Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, today announced first patient enrollment in AI-PREDICT, a retrospective, international, multicenter study designed to ...

FFR-CT and Stenosis under FDA review “We are standing at an inflection point in cardiovascular medicine, on the cusp of CCTA 3.0 and moving from population-based guidelines to truly personalized ...

Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared PlaqueIQ(TM) ...

BOSTON--(BUSINESS WIRE)--Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software based on ground truth histology to support treatment of cardiovascular ...

BOSTON--(BUSINESS WIRE)--Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has added ...

Elucid's new Lesion Inspection Tool for coronary and carotid plaque analysis in its Plaque-IQ software suite provides physicians the ability to interrogate lesion-specific composition and plaque ...

Opportunity to demo the only FDA-cleared, non-invasive plaque analysis based on objective ground truth histology, the gold standard for characterization of plaques Elucid CEO Kelly Huang, PhD, will ...